Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium

Ruvinov, Emil; Sharabani-Yosef, Orna; Nagler, Arnon; Einbinder, Tom; Feinberg, Micha S; Holbova, Radka; Douvdevani, Amos; Leor, Jonathan

doi:10.1186/1755-1536-1-7

Table 3 Comparison of LV remodeling and function between EPO-transduced, non-transduced cell or saline injections by two-dimensional echocardiography, before (baseline), or 5 or 9 weeks after MI

From: Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium

	EPO-transduced cells (n = 10)	Non-transduced cells (n = 9)	Saline (n = 9)	p ^†
5-week follow-up
Heart rate				0.17
Baseline	308.8 ± 12.6	273.8 ± 11.7	273.0 ± 11.6
5 weeks	252.7 ± 9.5	252.5 ± 14.0	262.8 ± 13.5
p*	0.0068	0.32	0.55
AW d (cm)				0.07
Baseline	0.13 ± 0.01	0.17 ± 0.007	0.13 ± 0.01
5 weeks	0.09 ± 0.006	0.10 ± 0.01	0.10 ± 0.01
p*	0.006	0.0002	0.04
LVEDD				0.08
Baseline	0.76 ± 0.02	0.72 ± 0.02	0.82 ± 0.02
5 weeks	1.06 ± 0.02	0.98 ± 0.03	1.00 ± 0.03
p*	<0.0001	<0.0001	0.0009
LVESD				0.22
Baseline	0.60 ± 0.03	0.56 ± 0.02	0.64 ± 0.03
5 weeks	0.88 ± 0.03	0.81 ± 0.04	0.80 ± 0.04
p*	<0.0001	<0.0001	<0.0001
LVEDA				0.34
Baseline	0.39 ± 0.03	0.35 ± 0.01	0.43 ± 0.02
5 weeks	0.73 ± 0.04	0.65 ± 0.04	0.67 ± 0.05
p*	<0.0001	<0.0001	0.0011
LVESA				0.36
Baseline	0.24 ± 0.02	0.21 ± 0.01	0.26 ± 0.02
5 weeks	0.52 ± 0.04	0.42 ± 0.04	0.44 ± 0.05
p*	<0.0001	<0.0001	0.0004
FS (%)				0.99
Baseline	20.6 ± 2.9	22.3 ± 1.7	25.07 ± 2.2
5 weeks	16.2 ± 1.4	17.8 ± 1.6	20.96 ± 2.0
p*	0.14	0.008	0.002
9-week follow-up
Heart rate				0.28
Baseline	303.2 ± 12.7	274.4 ± 13.3	273.0 ± 11.6
9 weeks	242.0 ± 6.3	235.5 ± 12.2	246.2 ± 7.7
p*	0.04	0.12	0.0014
AW d (cm)				0.19
Baseline	0.13 ± 0.01	0.17 ± 0.007	0.13 ± 0.01
9 weeks	0.09 ± 0.01	0.12 ± 0.01	0.11 ± 0.01
p*	0.03	0.0002	0.3
LVEDD				0.22
Baseline	0.76 ± 0.02	0.72 ± 0.02	0.82 ± 0.02
9 weeks	1.11 ± 0.04	1.03 ± 0.03	1.05 ± 0.03
p*	<0.0001	<0.0001	0.0003
LVESD				0.3
Baseline	0.60 ± 0.03	0.56 ± 0.02	0.64 ± 0.03
9 weeks	0.95 ± 0.05	0.84 ± 0.04	0.86 ± 0.05
p*	<0.0001	<0.0001	<0.0001
LVEDA				0.42
Baseline	0.39 ± 0.03	0.35 ± 0.01	0.43 ± 0.02
9 weeks	0.83 ± 0.06	0.71 ± 0.05	0.74 ± 0.06
p*	<0.0001	<0.0001	0.0006
LVESA				0.37
Baseline	0.24 ± 0.02	0.21 ± 0.01	0.26 ± 0.02
9 weeks	0.61 ± 0.06	0.48 ± 0.05	0.51 ± 0.06
p*	0.0001	0.0001	0.0003
FS (%)				0.09
Baseline	20.6 ± 2.9	22.3 ± 1.72	25.1 ± 2.2
9 weeks	14.3 ± 1.8	18.7 ± 1.73	19.8 ± 2.4
p*	0.05	0.02	0.0008

AW d, anterior wall diastolic thickness; LVEDD, LV end diastolic dimension; LVESD, LV end systolic dimension; LVEDA, LV end diastolic area; LVESA, LV end systolic area; FS, LV fractional shortening [(LVIDd – LVIDs)/LVIDd] × 100. Values are mean ± SEM; p*, p-values derived from paired comparisons between baseline and 5/9 week measurements; p^†, p-values for the differences between groups over time (two-way repeated-measures ANOVA, p-value for interaction).

Back to article page

ISSN: 1755-1536

Contact us

General enquiries: info@biomedcentral.com

Fibrogenesis & Tissue Repair

Contact us